医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BeiGene to Present at Upcoming Investor Conferences

2022年11月04日 PM08:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences:

  • The 6th Annual Cowen IO Next Virtual Conference on Friday, November 11, at 9:40 a.m. (ET); and
  • The 13th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 16 at 11:25 a.m. (ET).

A live webcast can be accessed from the investors section of BeiGene’s websites at https://ir.beigene.com, https://hkexir.beigene.com and https://sseir.beigene.com. An archived replay will be available for 90 days following the event.

About BeiGene
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221104005187/en/

CONTACT

Investor

Kevin Mannix

+1-857-302-5189

ir@beigene.com

Media

Kyle Blankenship

+1 667-351-5176

media@beigene.com

同じカテゴリーの記事 

  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究
  • ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology